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Background. Tumor irradiation combined with adjuvant treatments, either vascular targeted or immunomodulatory, 
is under intense investigation. Gene electrotransfer of therapeutic genes is one of these approaches. The aim of this 
study was to determine, whether gene electrotransfer of plasmid encoding shRNA for silencing endoglin, with vascular 
targeted effectiveness, can radiosensitize melanoma B16F10 tumors. 
Materials and methods. The murine melanoma B16F10 tumors, growing on the back of C57Bl/6 mice, were treated 
by triple gene electrotransfer and irradiation. The antitumor effect was evaluated by determination of tumor growth 
delay and proportion of tumor free mice. Furthermore, histological analysis of tumors (necrosis, apoptosis, prolifera-
tion, vascularization, presence of hypoxia and infiltration of immune cells,) was used to evaluate the therapeutic 
mechanisms. 
Results. Gene electrotransfer of plasmid silencing endoglin predominantly indicated vascular targeted effects of 
the therapy, since significant tumor growth delay and 44% of tumor free mice were obtained. In addition, irradiation 
had minor effects on radioresistant melanoma, with 11% of mice tumor free. The combined treatment resulted in ex-
cellent effectiveness with 88% of mice tumor free, with more than half resistant to secondary tumor challenge, which 
was observed also with the plasmid devoid of the therapeutic gene. Histological analysis of tumors in the combined 
treatment group, demonstrated similar mode of action of the gene electrotransfer of plasmid encoding shRNA for 
silencing endoglin and devoid of it, both through the induction of an immune response. 
Conclusions. The results of this study indicate that irradiation can in radioresistant melanoma tumors, by release of tu-
mor associated antigens, serve as activator of the immune response, besides directly affecting tumor cells and vascu-
lature. The primed antitumor immune response can be further boosted by gene electrotransfer of plasmid, regardless 
of presence of the therapeutic gene, which was confirmed by the high radiosensitization, resulting in prolonged tumor 
growth delay and 89% of tumor free mice that were up to 63% resistant to secondary challenge of tumor. In addition, 
gene electrotransfer of therapeutic plasmid for silencing endoglin has also a direct effect on tumor vasculature and 
tumors cells; however in combination with radiotherapy this effect was masked by pronounced immune response. 
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Introduction
Electroporation is used as drug delivery system 
for molecules with hampered transmembrane 
transport.1 It is effective for delivery of smaller 
molecules, as chemotherapeutics in electrochemo-
therapy (ECT)1-3 and also for larger molecules, as 
are plasmids in gene electrotransfer (GET). GET is 
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recently getting a lot of scientific consideration and 
it is used for enhanced DNA delivery into various 
tissue types (i.e. skin, liver, kidney etc.), as well as 
into tumors.4-6 Its effectiveness was first demon-
strated in a wide range of preclinical studies and 
has thereafter proceeded to clinical oncology, vet-
erinary and human. The results of clinical trials of 
GET of plasmid encoding human IL-127 and anti-
angiogenic plasmid AMEP8, are promising. In addi-
tion to GET of therapeutic plasmids, some plasmids 
devoid of therapeutic genes have also resulted in 
good antitumor effectiveness.9,10 This phenomenon 
was observed in different tumors models and by 
using different plasmids. It was attributed to im-
mune sensing of the introduced DNA as a DAMP 
(Damage Associated Molecular Pattern), which 
switch leads to activation of an immune response.11
Radiotherapy is one of the principal treatment 
modalities for primary tumors and their metasta-
ses.12 Nowadays, irradiation is widely investigated 
for its associated effects on priming antitumor im-
munity.13 There is growing evidence of irradia-
tion’s effect on the antitumor immune response, 
inducing immunogenic cell death and generating 
danger signals. An important danger signal after 
irradiation is DNA released from the nucleus of dy-
ing cells. This DNA is recognized by the immune 
system as a DAMP, and can promote the activation 
of immune response against irradiated cells.14,15
Studies combining tumor irradiation with GET 
of different therapeutic plasmid demonstrated tu-
mor radiosensitization.16-18 A promising approach 
to target tumors and its microenvironment with a 
combined treatment modality is through destruct-
ing abnormal tumor blood vessels. One of the 
promising targets, gaining on its value due to dif-
ferent signaling pathways from VEGF, is endoglin. 
It is a TGF-β coreceptor and has already demon-
strated good antitumor and antimetastatic effec-
tiveness in different tumor models when targeted 
with GET of plasmid.18–22 In particular, GET of 
shRNA for silencing endoglin in B16F10 melanoma 
mice tumors that express high levels of endoglin, 
resulted in up to 58% of tumor cures.23
Tissue specific eukaryotic promoters are tightly 
regulated and mainly drive expression of transgene 
in specific cell types, although minimal unspecific 
expression in non-targeted tissue can also occur.24 
We constructed a plasmid containing a tissue spe-
cific promoter for endothelin and encoding shRNA 
for silencing endoglin. This plasmid was tested in 
a previous study, where the effectiveness of the 
plasmid with tissue specific promoter was com-
pared to a plasmid with constitutive promoter 
in a tumor model that does not express targeted 
molecule, endoglin. In vivo, the effectiveness of the 
GET of the plasmids was comparable and resulted 
in significant radiosensitization, which resulted in 
prolonged tumor growth delay with nearly 50% of 
tumor free mice. Thus, the aim of this current study 
was to determine, whether GET of plasmid, with 
tissue specific promoter and encoding shRNA for 
silencing endoglin, can radiosensitize melanoma 
B16F10 tumors, which express targeted molecule, 
endoglin, and possibly have also some immu-
nomodulatory effectiveness. 
Materials and methods
Cell lines and plasmids
Murine melanoma cell line B16F10 (American 
Type Culture Collection, Manassas, VA, USA) 
was cultured in advanced minimum essential me-
dium (AMEM, Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA) supplemented with 5% fetal 
bovine serum (FBS, Gibco), 10 mM/L L-glutamine 
(GlutaMAX, Gibco), 100 U/mL penicillin 
(Grünenthal, Aachen, Germany) and 50 mg/mL 
gentamicin (Krka, Novo mesto, Slovenia) in a 5% 
CO2 humidified incubator at 37°C. 
The plasmid with tissue specific promoter for 
endothelial cells, encoding shRNA for silencing 
endoglin (pET-antiCD105; TS plasmid) was used in 
experiments as the therapeutic plasmid.18 The con-
trol plasmid, encoding shRNA with no homology to 
any gene in the mouse genome and with constitu-
tive CMV promoter, was used as a negative control 
(pControl).25 Amplification of both plasmids was 
performed in a competent E.coli (JM107; Invitrogen, 
Thermo Fisher Scientific, Waltham, MA, USA). 
All plasmids were isolated using JETSTAR 
2.0 ENDOTOXIN-FREE Plasmid MEGA Kit 
(Genomed, Löhne, Germany) and diluted in endo-
toxin free water to a concentration of 1 μg/μL (in vit-
ro experiments) and 4 μg/μL (in vivo experiments). 
Concentrations of plasmids were measured with a 
spectrophotometer at 260 nm (Epoch Microplate 
Spectrophotometer, Take3 Micro-Volume Plate, 
BioTek, Bad Friedrichshall, Germany) and purity 
of plasmid was determined by agarose gel elec-
trophoresis and measurements of the absorbance 
ratio at 260 and 280 nm.
Experimental animals 
All animal experiments were conducted in accord-
ance with the guidelines for animal experiments of 
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the EU Directive and the permission obtained from 
the Ministry of Agriculture and the Environment 
of the Republic of Slovenia (Permission No. 34401-
1/2015/16), which was given, based on the approval 
of the National Ethics Committee for Experiments 
on Laboratory Animals). 
Female C57Bl/6 mice, 6-8-week old, purchased 
from Envigo Laboratories (Udine, Italy), were 
used in the study. Before the experiment, mice 
were subjected to an adaptation period of 2 weeks. 
Animals were maintained under specific patho-
gen-free conditions at a constant room tempera-
ture, humidity and a 12 h light/dark cycle. Food 
and water were provided ad libitum. For induction 
of subcutaneous tumors, a suspension of 1x106 
B16F10 cells in 0.1 ml of physiological saline was 
injected subcutaneously into the back of the mice. 
The animals bearing tumors of 40 mm3 were ran-
domly divided into experimental groups and sub-
jected to a specific experimental protocol. The tu-
mor measurements were completed when the tu-
mors reached 350 mm3, and mice were humanely 
sacrificed. 
Experimental groups and the number of animals 
in each of them were as follows and as described in 
table Table 1: triple injection of endotoxin-free wa-
ter alone (control group; CTRL) or of pControl or 
TS plasmids alone, or in combination with triple 
application of electric pulses alone (3 × EP) or com-
bined with plasmids (3 × GET (pControl); 3 × GET 
(TS)). Furthermore, the remaining groups were 
also the ones in combination with irradiation (IR) 
and other therapies described above, which are 
three injections of plasmids (pControl + IR; TS + IR) 
and in combination with electric pulses (3 × EP + 
IR; 3 × GET (pControl) + IR; 3 × GET (TS) + IR). 
In vivo GET 
In vivo GET of plasmid into subcutaneous tumors 
was performed 3 times every second day (on days 
0, 2 and 4). 12.5 μL (4 μg/μL) of plasmid (150 μg in 
total) in endotoxin-free H2O was injected intratu-
morally 10 min before 8 square electric pulses with 
a voltage-to-distance ratio of 600 V/cm, a pulse du-
ration of 5 ms, and a frequency 1 Hz were applied. 
Electric pulses were generated by electric pulse 
generator ELECTRO CELL B10 (Betatech, L’Union, 
France) and delivered through 2 parallel stainless 
steel electrodes with 2 or 4 mm distance between 
them, depending on the tumor volume. After 4 
pulses, electrodes were turned for 90° for 4 addi-
tional pulses to assure GET to entire tumor.
Irradiation of tumors
Tumors were locally irradiated with a single dose 
of 15 Gy on day 1 from the beginning of the experi-
ment, at a dose rate of 2.16 Gy/min, using a Darpac 
2000 X-ray unit (Gulmay Medical Ltd., Shepperton, 
UK) operating at 220 kV, 10 mA, with 1.8-mm alu-
minum filtration. During irradiation, mice were 
TABLE 1. Response of B16F10 melanoma to different treatment modalities 
Therapeutic group
DT (days) TGD (days) TF SC
n AM  SEM AM  SEM n % n %
CTRL 8 1.2 ± 0.1 0.0 ± 0.1 0 0 - -
pControl 8 1.9 ± 0.2 0.7 ± 0.2 0 0 - -
TS 8 2.2 ± 0.3 1.0 ± 0.3 0 0 - -
3 × EP 8 3.1 ± 0.3 2.0 ± 0.3 0 0 - -
3 × GET (pControl) 8 9.4 ± 6.5 8.2 ± 2.5 0 0 - -
3 × GET (TS) 9 9.5 ± 3.2 8.6 ± 3.0 4 44 3 75
IR 9 1.8 ± 0.3 0.7 ± 0.3 0 0 - -
pControl + IR 9 2.5 ± 0.3 1.3 ± 0.3 1 11 1 100
TS + IR 8 4.0 ± 1.2 2.8 ± 1.2 0 0 - -
3 × EP+IR 9 4.3 ± 1.3 3.2 ± 1.3 2 22 0 0
3 × GET (pControl) + IR 9 36.0 ± n/a 34.9 ± n/a 8 89 5 63
3 × GET (TS) + IR 8 32.0 ± n/a 30.8 ± n/a 7 88 4 57
AM = Arithmetic mean; DT = Tumor doubling time; Groups: (CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pET-
antiCD105); n = Number of all mice in the group; n/a = Not applicable; SC = Mice resistant to secondary challenge; SEM = Standard error; TF = Tumor 
free mice; TGD = Tumor growth delay
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restrained in special lead holders with apertures 
for irradiation of the tumors. Due to the fixed size 
of the apertures, some healthy tissue (3 – 5 mm of 
skin surrounding the tumor) was exposed to the 
irradiation as well. 
Tumor growth
The therapeutic potential in vivo was assessed by 
measuring the tumor size every second day and 
calculating tumor volume according to the for-
mula for ellipsoid: V=axbxc π/6, where a, b and c 
represent perpendicular tumor diameters.21,26 The 
tumor growth curves were drawn as arithmetic 
means (AM) with bars representing standard er-
rors (SEM). 
The tumor growth delay for each experimen-
tal group was calculated as the difference in tu-
mor doubling times of experimental and control 
groups. Tumor doubling time is the number of 
days in which the initial tumor volume (40-50 mm3) 
doubles. Mice that remained tumor free for 70 days 
were termed tumor free and local tumor control 
was deemed to have been achieved (Table 1). The 
weight of the mice was followed as a general in-
dex of systemic toxicity, and acute skin reaction in 
the whole irradiated field around the tumor was 
evaluated as described elsewhere.17
Tumor challenge of tumor free mice
After 70 days, when mice were designated as tu-
mor free, they were challenged with a subcuta-
neous injection of 1 × 106 B16F10 cells in 0.1 ml of 
physiological saline in the right flank. Mice that at 
least 20 days after the challenge remained tumor 
free were marked as resistant to secondary chal-
lenge (Table 1, Figure 2). The growing tumors were 
measured twice a week and when volume of 150 
mm3 was reached mice were sacrificed and tumors 
were collected for further histological analysis as 
described below.
Histology
After therapies, at day 6, three mice from each ex-
perimental group were sacrificed. The tumors were 
excised, fixed in IHC zinc fixative (BD Biosciences, 
San Diego, CA, USA) and embedded in paraffin. 
Six consecutive 2-μm thick sections were cut from 
each paraffin block and stained as followed. To 
estimate the percent of the area of tumor necro-
sis, the first section was stained with hematoxylin 
and eosin. The other five sections were used for 
immunohistochemical (IHC) staining to evaluate 
percentage of hypoxic cells, cells in apoptosis, im-
mune cells, proliferating cells and the number of 
blood vessels. To determine hypoxic cells, rabbit 
polyclonal antibodies against HIF-1-alpha (ab2185, 
Abcam, Cambridge, MA, USA) at dilution 1:3500, 
were used. In addition, apoptosis was evaluated 
with help of cleaved Caspase-3 (Asp175., Cell sign-
aling Technology, Danvers, MA, USA) at dilution 
1:1500, whereas immune cells (NK and CTL) were 
stained with help of Granzyme B (ab4059, Abcam) 
at dilution 1:1250. For staining proliferating cells, 
rabbit monoclonal antibodies against Ki-67 (clone 
SP6, Thermo Fisher Scientific) at dilution 1:1200 
were used. The last section was stained for deter-
mination of the number of blood vessels, by using 
primary rabbit polyclonal antibodies against CD31 
(ab28364, Abcam) at dilution 1:1000. For these sec-
tions, a peroxidase-conjugated streptavidin–biotin 
system (Rabbit specific HRP/DAB detection IHC 
kit, ab64261, Abcam) was used as the colorogenic 
reagent followed by hematoxylin counterstaining. 
From each slide and each feature (apoptosis, hy-
poxia, proliferation, vascularisation and immune 
cells), five randomly selected viable parts of each 
tumor were observed and captured under the light 
FIGURE 1. Histological sections of melanoma tumors on day 6 after the beginning of the therapy.
CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pET-antiCD105
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microscopy, by DP72 CCD camera (Olympus, 
Hamburg, Germany) connected to a BX-51 micro-
scope (Olympus) under 40× magnification (numer-
ical aperture 0.85). The viable parts were analyzed 
in blind fashion and the results were presented 
as the percent (hypoxia, apoptosis, proliferation) 
of the cells or the number of cells (immune cells) 
or the structures (vascularization) positive to IHC 
staining. The percentage of necrosis was contribut-
ed to the tumors as whole and was also evaluated 
in blind fashion, as previously described.18
In addition, tumors that grew up to 150 mm3 after 
secondary challenge of tumors, were excised, fixed 
and embedded in paraffin, as described above. 
Furthermore, from each tumor sections were cut 
and stained with hematoxylin and eosin to deter-
minate morphological changes of tumor cells. 
Statistical analysis
All data were tested for normality of distribu-
tion with the Shapiro-Wilk test. The differences 
between the experimental groups were statisti-
cally evaluated by one-way analysis of variance 
(one-way ANOVA) followed by a Holm-Sidak test 
for multiple comparison. A P-value of less than 
0.05 was considered to be statistically significant. 
SigmaPlot Software (Systat Software, Chicago, IL, 
USA) was used for statistical analysis and graphi-
cal representation.
FIGURE 2. Immune response of melanoma tumors is observed by vitiligo effect.
CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pET-antiCD105
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Results
Gene electrotransfer of plasmid 
silencing endoglin indicates a vascular 
targeted effects of the therapy
GET of either plasmids (pControl, TS) to melanoma 
tumors had statistically significant antitumor ef-
fectiveness compared to untreated tumors, which 
resulted in 8.2 ± 2.5 and 8.6 ± 3.0 days of tumor 
growth delay, respectively (Table 1). However, 
GET (TS) resulted in 44% of tumor free mice and 
75% of them were resistant to secondary challenge, 
whereas in the GET (pControl) group no tumor free 
mice were obtained. Histological analysis (Table 2) 
of GET (TS) group demonstrated reduction of vas-
cularization (14.9 ± 1.1%) and proliferating cells 
(49.5 ± 3.8%), whereas hypoxia (46.3 ± 3.0%) lev-
els were increased and statistically significant to 
at least pertinent control groups (CTRL, pControl, 
TS and 3 × GET (pControl)). The levels of necrosis, 
apoptosis and number of infiltrating immune cells 
in the tumors were comparable in both GET treat-
ment modalities (Figure 1) and statistically signifi-
cant to at least CTRL, pControl and TS. These re-
sults indicated the vascular targeted effects of the 
GET (TS), used for silencing endoglin. 
Irradiation, alone or combined 
either with plasmids injection or 
electric pulses, had minor effect on 
radioresistant melanoma tumors 
Irradiation monotherapy with 15 Gy had minor 
effects on radioresistant melanoma tumor. The 
tumor growth delay was moderate in the groups 
of irradiation alone or in combination with injec-
tion of plasmids (from 0.7 ± 0.3 to 2.8 ± 1.2 days) 
and up to 11% of tumor free mice were obtained 
in the group of irradiation in combination with in-
jection of plasmid pControl (Table 1). The results 
of histological analysis (Table 2, Figure 1) indicates 
an immunological effect of the irradiation alone or 
in combination with plasmids injection, since the 
number of infiltrating immune cells in the tumors 
was statistically significantly higher in comparison 
to control groups (CTRL, pControl, TS) and groups 
applying electric pulses (alone or combined with 
injection of plasmids (GET (pControl) and GET 
(TS)), and the tumor free mice were resistant to sec-
ondary challenge. Furthermore, irradiation alone 
caused the reduction in proliferating cell levels 
(53.3 ± 3.5%) and in tumor vascularization (30.1 ± 
2.3%), whereas apoptosis (18.4 ± 1.8%) and hypox-
ia (30.2 ± 2.4%) levels were elevated. All of these 
results were statistically significant compared to 
CTRL, pControl and TS groups.
The application of electric pulses to tumors in 
combination with tumor irradiation resulted in bet-
ter antitumor effectiveness than observed in each 
of these two treatment modalities alone. The tumor 
growth delay in combined treatment was 3.2 ± 1.3 
days and 22% of tumor free mice were obtained 
(Table 1). The histological analysis of combined 
treatment demonstrated statistically significant 
higher levels of apoptosis (31.0 ± 2.0%) and hypoxia 
(51.7 ± 2.6%) in comparison to the groups of irradi-
ation and electric pulses alone. Among these three 
groups no statistically significant differences were 
observed in the levels of necrosis. Furthermore, the 
analysis of levels of proliferating cells, the number 
of tumor blood vessels and immune cells infiltrat-
ing in the tumors, resulted in similar and moder-
ate effectiveness of the combined treatment (3 × 
EP + IR) and irradiation (alone or combined with 
injection of plasmids), which statistically signifi-
cantly differed from group of electric pulses alone. 
Nevertheless, in this combined treatment modality 
(3 × EP + IR) no tumor free mice were resistant to 
secondary challenge of tumors.
Combination of GET and irradiation 
exerts pronounced antitumor effects
The groups combining GET of plasmids (pControl, 
TS) and irradiation resulted in pronounced thera-
peutic effectiveness, with up to 89% and 88% of 
tumor free mice, respectively, and from those up 
to 63% and 57% of mice was resistant to second-
ary tumor challenge, respectively (Table 1). The 
histological analysis, of tumors excised 6 days after 
treatment (Table 2, Figure 1), indicated on similar 
mode of action of these combined treatment mo-
dalities (3 × GET (pControl or TS) + IR), since the 
elevation of necrosis (65.0 ± 7.6%, 79.2 ± 4.2%), 
number of immune cells (45.8 ± 3.0%, 46.5 ± 2.1%), 
reduction of tumor vascularization (18.9 ± 2.0%, 
12.8 ± 1.0%) and proliferation (46.0 ± 4.8%, 46.7 ± 
4.8%), did not differ between these groups. Only 
two statistically significant differences between 
the therapeutic groups combining GET (pControl, 
TS) and irradiation were observed which were the 
level of hypoxia (58.0 ± 2.8%, 66.7 ± 1.6%), and ap-
optosis (38.7 ± 3.1%, 50.3 ± 2.4%). 
The high number of infiltrating immune cells 
(Table 2) in these tumors indicated on important 
mode of this therapeutic action; the highest and 
statistically significantly increased number of im-
mune cells was observed in the groups combin-
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ing GET of plasmids and irradiation, followed by 
all the remaining groups that included irradiation 
(alone, TS, pControl and 3 × EP). In these groups, 
the immune cells infiltration was comparable and 
statistically significant to all of the other remaining 
groups. Furthermore, the immune cells infiltration 
was the lowest in the groups that included electric 
pulses (alone or with plasmids alone). Additionally, 
all of the mice that were tumor free after the thera-
pies including irradiation, either alone or in combi-
nation with other modalities, had fur discoloration, 
known as vitiligo, indicating immune response 
(Figure 2). This was further confirmed with high 
number of mice that were resistant to secondary 
challenge in tumor free mice, with the exception of 
the group combining electric pulses and irradiation 
(Table 1). In these groups, in which tumors grew af-
ter secondary challenge, the growth rate and histol-
ogy of the tumors were the same as after the initial 
induction of tumors (data not shown). 
In addition, the safety of the treatment (irradia-
tion alone or in combination with other modalities) 
was proven, since no body weight loss over 10%, or 
any other side effects were observed, except for the 
temporary hair loss in the irradiated area, without 
skin desquamation (data not shown). 
Discussion
The results of this study indicate a dual effect of 
GET of plasmid encoding shRNA for silencing 
endoglin, the direct and the indirect, both having 
a radiosensitizing effect. The direct effect was on 
the tumor vasculature and also on melanoma tu-
mor cells, whereas the indirect was observed with 
the use of plasmid devoid of therapeutic gene, 
through boosting the immune response in tumors. 
Furthermore, irradiation had mainly affected mel-
anoma cells, although some effect on vasculature 
could also be noticed. In addition, the higher num-
ber of infiltrating immune cells in all of the groups 
combined with irradiation indicated an important 
role of the immune system. All of these effects had 
synergistic action and, in combined treatment mo-
dality of GET and irradiation, resulted in increased 
radiosensitizing effectiveness of melanoma tumors 
that resulted in prolonged tumor growth delay, 
which led to 88% of tumor free mice, of which 57% 
were resistant to secondary challenge of tumors.
Dual effectiveness of GET 
The first direct effect of GET (TS) was on tumor 
vasculature, which was significantly reduced after 
the treatment. This vascular effect can be ascribed 
to the specificity of the plasmid for endothelial cells 
and to the endoglin silencing. This direct effect on 
tumor vasculature was also observed in other stud-
ies using GET of plasmid for silencing endoglin on 
melanoma22,23 and other tumor models.18,19,21 The 
vascular targeted effects in these studies were first 
confirmed in non-endoglin expressing tumors, i.e. 
murine mammary adenocarcinoma, by endotheli-










Vascularization    
(n of structures)
Immune cells
 (n of cells)
AM SEM AM SEM AM SEM AM SEM AM SEM AM SEM
CTRL 25.0 ± 2.6 11.3 ± 1.6 4.7 ± 1.0 92.2 ± 1.3 51.6 ± 3.2 7.9 ± 0.9
pControl 20.0 ± 2.6 11.6 ± 1.0 5.4 ± 1.0 92.1 ± 1.2 47.1 ± 4.7 8.3 ± 1.1
TS 21.7 ± 2.6 11.4 ± 1.5 5.5 ± 0.7 92.7 ± 1.0 50.5 ± 4.2 7.9 ± 0.7
3 × EP 13.3 ± 3.6 18.7 ± 2.7 7.8 ± 0.8 74.4 ± 1.7 39.9 ± 2.6 14.3 ± 1.7
3 × GET (pControl) 53.3 ± 7.9 19.5 ± 3.0 15.3 ± 2.9 75.6 ± 2.4 35.3 ± 4.2 15.1 ± 1.6
3 × GET (TS) 65.8 ± 7.6 26.7 ± 2.2 46.3 ± 3.0 49.5 ± 3.8 14.9 ± 1.1 19.3 ± 1.7
IR 21.7 ± 4.2 18.4 ± 1.8 30.2 ± 2.4 53.3 ± 3.5 30.1 ± 2.3 26.8 ± 2.6
pControl + IR 37.5 ± 8.0 18.7 ± 1.9 32.3 ± 2.5 54.5 ± 4.7 24.5 ± 1.8 26.4 ± 2.1
TS + IR 43.3 ± 8.0 19.9 ± 1.5 31.6 ± 2.3 52.0 ± 2.9 23.8 ± 1.6 26.4 ± 2.3
3 × EP + IR 25.0 ± 4.8 31.0 ± 2.0 51.7 ± 2.6 59.4 ± 4.0 28.9 ± 2.3 29.3 ± 2.1
3 × GET (pControl) + IR 65.0 ± 7.6 38.7 ± 3.1 58.0 ± 2.8 46.0 ± 4.8 18.9 ± 2.0 45.8 ± 3.0
3 × GET (TS) + IR 79.2 ± 4.2 50.3 ± 2.4 66.7 ± 1.6 46.7 ± 4.8 12.8 ± 1.0 46.5 ± 2.1
AM = Arithmetic mean; Groups: (CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pET-antiCD105); n = Number of structures or cells; SEM = Standard error
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al-specific promoter18,21 and non-specific, constitu-
tive promoter18–21, that resulted in pronounced an-
titumor effectiveness. In melanoma tumor model, 
B16F10-luc, the GET of plasmids silencing endog-
lin resulted in significant antimetastatic effective-
ness.22 Furthermore, GET of plasmid silencing 
endoglin, with constitutive promoter, performed 
on small melanoma B16F10 tumor model (4 mm3 
at the beginning of therapy) confirmed vascular 
targeted effects, which resulted in prolonged tu-
mor growth delay and tumor free mice (58%), also 
due to nonspecific nature of constitutive plasmid 
that was used in this study silenced endoglin also 
in melanoma cells.23 Nevertheless, in the current 
study, which was done on bigger tumors (40 mm3), 
in addition to significant increased level of hypox-
ia, also decreased number of proliferating tumor 
cells was observed. This was attributed to the sec-
ond direct effect of GET (TS), that is silencing of 
endoglin also in melanoma cells, since it is known 
that plasmid with tissue specific promoters can be 
leaky and can also be transcribed in non-targeted 
tissue.27 Therefore, GET (TS) has dual direct effects; 
primarily by targeting vasculature and secondly by 
inhibition of proliferation of melanoma cells. These 
two effects together resulted in 44% of tumor free 
mice, from which 75% were resistant to secondary 
challenge of tumor cells. 
Nevertheless, high level of infiltrating immune 
cells in the tumors, indicated also an indirect ef-
fect of this treatment, through the stimulation of 
immune response. This is also supported by the 
data obtained with GET of the plasmid devoid of 
therapeutic gene (pControl). In comparison to GET 
of therapeutic plasmid, TS, no tumor cures were 
obtained, however, in other measured parameters, 
infiltration of immune cells into the tumors, lev-
els of necrosis and apoptosis as well as in tumor 
growth delay no statistically significant differenc-
es were obtained between these groups. Thus, to 
a certain degree, a similar mode of antitumor ac-
tion can be ascribed to the GET of plasmid DNA, 
mainly because the values of these parameters 
were statistically different from pertinent control 
groups. Antitumor effectiveness of GET of non-
therapeutic (control) plasmids was also observed 
in other studies9,10, and the authors indicated that 
effectiveness was due to involvement of immune 
system. Namely, the plasmid introduced during 
GET can act as a DAMP that is recognized through 
different sensors (Pattern Recognition Receptors), 
leading to the activation of the signal transduction 
cascade that ultimately triggers the production 
of type 1 interferons and other cytokines.28 These 
act as a link between the innate and adaptive im-
mune response29 and can induce the adaptive im-
mune response against the introduced DNA and 
consequently the transfected cells. Furthermore, 
similar immune response can also be triggered by 
the stress30 that is produced during the transfection 
procedure, like mechanical stress, heat, and ROS, 
that have all been previously reported after elec-
troporation.31,32 
Priming effect of irradiation
To target primary tumors, as was done in this 
study, irradiation is one of the most used treatment 
modalities.33 This therapeutic approach alone or 
in combination with injection of plasmids, in ra-
dioresistant melanoma tumor model, resulted in 
moderate tumor growth delay, which was attrib-
uted to decreased proliferation of melanoma cells, 
increased levels of apoptosis and necrosis. Further 
histological analysis indicated on the radiation 
damage of the tumor vasculature, as a second ef-
fect of the irradiation, as seen in other studies.34,35 
This vascular damage was less pronounced than in 
group of GET (TS), although in comparison to GET 
(TS), irradiation monotherapy resulted in high-
er infiltration of the immune cells in the tumors. 
Furthermore, in the group combining irradiation 
and injection of therapeutic plasmid, one mouse 
was tumor free, which was also resistant to sec-
ondary challenge of tumor. This indicates a prim-
ing effect of irradiation combined with introduc-
tion of foreign DNA, through boosting the immune 
response. When irradiated cells die, they release 
their antigens in the context of the danger signal 
(DAMPS), which result in the priming of a tumor 
specific immune response against the released an-
tigens. Therefore, irradiated tumors can sometimes 
act as a powerful individualized in situ vaccine13, 
which is manifested as the abscopal effect of the ir-
radiation. This was confirmed in in vivo studies in-
dicating that irradiation can induce in vivo priming 
of T cells to exogenous model antigens engineered 
to be expressed by tumors.13 In melanoma tumor 
model, priming of antitumor T cells to the model 
antigen ovalbumin, was more effective when sin-
gle, 15 Gy dose was used, rather than 3 Gy given in 
5 consecutive days.36 Further on, another group al-
so showed induction of antitumor T-cell responses 
with other antigen expression, when single 20 Gy 
dose was applied, but not by 5 Gy given 4 times.37 
The combination of electric pulses and irradia-
tion exerted moderate antitumor effectiveness that 
resulted in 22% of tumor free mice. Similar results 
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were obtained in our previous studies on mu-
rine mammary adenocarcinoma18, sarcoma17 and 
Ehrlich-Lettre ascites38, where also 20%, 27% and 
54% of tumor free mice were observed, respective-
ly. Therefore we can assume that electroporation of 
tumors contributes to radioresponsiveness of mel-
anoma, most probably due to generation of ROS32,39 
after application of the electric pules, which also re-
sulted in significantly elevated levels of hypoxia in 
our histological analysis.
Immune boosting and radiosensitization 
by plasmid DNA
The combined treatment modalities (combination 
of GET (TS or pControl) with irradiation) exerted 
excellent, highly statistically significant antitumor 
effect in comparison to control groups, which re-
sulted in 88% and 89% of tumor free mice, respec-
tively, of which 57% and 63% of mice were resist-
ant to secondary challenge of tumors, respectively. 
The results of histological analysis were similar 
between groups of combined treatment modality 
(GET + IR), regardless of the applied plasmid. The 
only two differences were on the levels of apop-
tosis and hypoxia. The analysis of the presence of 
the immune cells showed on the highest number of 
the immune cells in the groups of GET of plasmids 
and irradiation, followed by irradiation groups 
(alone or combined with injections of plasmids or 
combined with electric pulses). Therefore, it can be 
presumed that the priming effect of irradiation can 
be boosted by GET of the plasmid DNA to fully ex-
ert vaccinating effect. Additionally, fur discolora-
tion, vitiligo, an immune-mediated destruction of 
normal melanocytes that has also been recognized 
as a positive prognostic indicator for treatment re-
sponse40,41, was also observed in this study in all 
the groups where tumor free mice were observed 
(except 3 × GET (TS)). In addition, majority of the 
tumor free mice were resistant to secondary chal-
lenge of tumors, further indicating on the develop-
ment of the immune memory. The tumors in exper-
imental groups, which were resistant to secondary 
challenged of tumor, were therefore radiosensibi-
lized through GET of plasmid, since in the group 
combining electric pulses and irradiation, no mice 
resulted resistant to secondary challenge of tumor. 
The GET of plasmids in combination with irradia-
tion presumably generated many danger signals 
that collectively define immunogenic cell death.13 
Furthermore, the immunogenicity of tumor 
might also play an important role in combined 
treatment modality.42 In the current study we ob-
tained significant antitumor effectiveness and up 
to 89% of tumors free mice, that were up to 63% 
resistant to secondary challenge of tumors, when 
combining GET and irradiation in melanoma tu-
mor model. Furthermore, in our previous study 
combining the same treatment modality on a dif-
ferent tumor model, murine mammary adenocar-
cinoma TS/A, we achieved up to 44% of tumors 
free mice with therapeutic plasmid silencing en-
doglin and 20% tumor free mice with the control 
plasmid.18 We can presume that the boosting of 
immune response depends on the tumor type, 
melanoma being more immunogenic that mam-
mary adenocarcinoma TS/A. Nevertheless, the 
mechanisms of these therapies are not fully elu-
cidated. Currently, we presume that there is in-
volvement of DNA sensors, ROS and specific im-
mune response after irradiation, but further stud-
ies are needed.
Conclusions
The results of this study indicate that irradiation 
can in radioresistant mice tumors, such as mela-
noma, by release of tumor associated antigens 
serve as the target of the immune response. This 
can be further boosted by GET of plasmid, with or 
without therapeutic gene, which was confirmed by 
the equal radiosensitization resulting in prolonged 
tumor growth delay and up to 89% of tumor free 
mice, which kept immune memory to melanoma 
cells. In addition, GET of therapeutic plasmid si-
lencing endoglin has also direct effect on vascu-
lature and tumors cells; however in combination 
with radiotherapy this effect was masked by pro-
nounced immune response. 
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